Brivaracetam is an anti-epileptic medication used to treat seizures. In this trial, it is being studied as a standalone treatment (monotherapy) for people with childhood absence epilepsy or juvenile absence epilepsy. This medication works by reducing abnormal electrical activity in the brain that causes absence seizures, which are brief periods where a person appears to blank out or stare into space.

Childhood Absence Epilepsy – A form of epilepsy that typically begins between ages 4 and 10, characterized by brief periods of unconsciousness where the person appears to be staring blankly. During these absence seizures, which typically last 10-15 seconds, the person stops their current activity and is unaware of their surroundings. The seizures can occur multiple times throughout the day, often disrupting daily activities such as school work. This condition typically manifests with a characteristic pattern on EEG recordings.

Juvenile Absence Epilepsy – A type of epilepsy that usually begins between ages 10-17, featuring absence seizures similar to those in childhood absence epilepsy but typically occurring less frequently. The seizures involve brief periods of unconsciousness where the person appears to be daydreaming or staring into space. These episodes typically last 10-20 seconds and can occur several times per day. The condition shows specific electrical patterns in the brain during seizures.